Sotorasib Reveals Anti|Tumor Efficacy in KRAS G12C|Positive ...

Sotorasib Reveals Anti-Tumor Efficacy in KRAS G12C-Positive ...

Sotorasib Reveals Anti-Tumor Efficacy in KRAS G12C-Positive Advanced Pancreatic Cancer ... New results from the advanced pancreatic cancer cohort ...

Sotorasib for Lung Cancers with KRAS p.G12C Mutation - PMC

Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer ...

2-Year Analysis of CodeBreaK 100 - ASCO Publications

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of ...

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients ...

2-Year Follow-Up Shows Sotorasib Significantly Prolongs Survival ...

FDA-approved therapy targets G12C mutation of KRAS gene · Overall survival rate after sotorasib: 50.8% at 1 year, 32.5% at 2 years · Reduced ...

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non–small-cell lung ...

LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND ...

LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC ...

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer

G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously ...

Sotorasib shows clinically meaningful activity in KRAS G12C ...

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety ...

Sotorasib in KRAS G12C-mutated non-small cell lung cancer

First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC.

FDA Issues Complete Response Letter to Sotorasib for KRAS G12C ...

... sotorasib for patients with KRAS G12C–mutated non–small cell lung cancer ... Repotrectinib shows promising efficacy in ROS1-positive NSCLC and ...

Sotorasib Produces Promising and Clinically Meaningful Efficacy in ...

Sotorasib (Lumakras) demonstrated encouraging and clinically meaningful anticancer activity coupled with a positive benefit-risk profile in ...

The next-generation KRAS inhibitors…What comes after sotorasib ...

Currently, sotorasib and adagrasib have been approved by the US FDA to treat patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation.

Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C ...

Background: The KRAS G12C mutation, prevalent in various malignancies, including non-small cell lung cancer (NSCLC), represents a unique therapeutic target.

Sotorasib Shows Activity in KRAS G12C–Mutated Pancreatic Cancer

Sotorasib is an irreversible KRAS G12C inhibitor that has been approved by the U.S. Food and Drug Administration for the treatment of non–small ...

Sotorasib Shows Long-Term Efficacy in Metastatic NSCLC with ...

Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the ...

Anticancer Efficacy of KRAS G12C Inhibitors Is Potentiated by PAK4 ...

KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors.

2-Year Follow-up Shows Durable Responses With Sotorasib in ...

Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to ...

First-Line Sotorasib Shows Long-Lasting Responses in Metastatic ...

Sotorasib continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with the KRAS G12C mutation at the 2-year follow-up of the phase 2 ...

Lead-In Dosing of Sotorasib Plus Pembrolizumab Shows Promising ...

... efficacy and relatively low rates of hepatotoxicity in patients with KRAS G12C–positive non–small cell lung cancer.